CL2008002161A1 - Compuestos derivados de pirazol de fórmula (i); procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardíaco, isquemia, cardiomiopatía, enfermedad de crohn, esclerosis múltiple, dolor neuropático. - Google Patents

Compuestos derivados de pirazol de fórmula (i); procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardíaco, isquemia, cardiomiopatía, enfermedad de crohn, esclerosis múltiple, dolor neuropático.

Info

Publication number
CL2008002161A1
CL2008002161A1 CL2008002161A CL2008002161A CL2008002161A1 CL 2008002161 A1 CL2008002161 A1 CL 2008002161A1 CL 2008002161 A CL2008002161 A CL 2008002161A CL 2008002161 A CL2008002161 A CL 2008002161A CL 2008002161 A1 CL2008002161 A1 CL 2008002161A1
Authority
CL
Chile
Prior art keywords
compound
disease
cardiomyopathy
crohn
ischemia
Prior art date
Application number
CL2008002161A
Other languages
English (en)
Inventor
Mattei Patrizio
Binggeli Alfred
Ricklin Fabienne
Aebi Johannes
Green Luke
P Maerki Hans
Hartmann Guido
Roche Oliver
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39816951&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002161(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2008002161A1 publication Critical patent/CL2008002161A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos derivados de pirazol; procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardiaco, isquemia, cardiomiopatía, enfermedad de Crohn, esclerosis múltiple, dolor neuropático.
CL2008002161A 2007-07-26 2008-07-24 Compuestos derivados de pirazol de fórmula (i); procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardíaco, isquemia, cardiomiopatía, enfermedad de crohn, esclerosis múltiple, dolor neuropático. CL2008002161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113173 2007-07-26

Publications (1)

Publication Number Publication Date
CL2008002161A1 true CL2008002161A1 (es) 2009-05-22

Family

ID=39816951

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002161A CL2008002161A1 (es) 2007-07-26 2008-07-24 Compuestos derivados de pirazol de fórmula (i); procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardíaco, isquemia, cardiomiopatía, enfermedad de crohn, esclerosis múltiple, dolor neuropático.

Country Status (15)

Country Link
US (1) US7977358B2 (es)
EP (1) EP2182953A2 (es)
JP (1) JP2010534631A (es)
KR (1) KR20100039416A (es)
CN (1) CN101765430A (es)
AR (1) AR067674A1 (es)
AU (1) AU2008280186A1 (es)
BR (1) BRPI0813836A2 (es)
CA (1) CA2693187A1 (es)
CL (1) CL2008002161A1 (es)
PE (1) PE20090893A1 (es)
RU (1) RU2010106397A (es)
SG (1) SG175583A1 (es)
TW (1) TW200911785A (es)
WO (1) WO2009013211A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2443689C2 (ru) 2005-11-21 2012-02-27 Сионоги Энд Ко., Лтд. ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЕ 1 ТИПА
EP2163543B1 (en) 2007-05-18 2015-03-04 Shionogi&Co., Ltd. Nitrogen-containing heterocyclic derivative having 11 beta-hydroxysteroid dehydrogenase type i inhibitory activity
TW201011009A (en) * 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
PE20120061A1 (es) 2008-12-19 2012-02-19 Boehringer Ingelheim Int Derivados de pirimidina como antagonistas del receptor ccr2
BR112012015873B1 (pt) 2009-12-17 2021-06-01 Centrexion Therapeutics Corporation Antagonistas de receptores ccr2
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
EP2688882B1 (en) 2011-03-25 2015-05-13 Boehringer Ingelheim International GmbH Pyrazole compounds as crth2 antagonists
AU2012311061B2 (en) 2011-09-23 2016-08-18 Advinus Therapeutics Limited Amide compounds, compositions and applications thereof
US9289365B2 (en) * 2011-10-24 2016-03-22 Avon Products, Inc. Compositions and methods for stimulating collagen synthesis in the skin
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
CA2936111C (en) 2014-01-06 2023-03-14 Algomedix, Inc. Trpa1 modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016087352A1 (en) * 2014-12-02 2016-06-09 F. Hoffmann-La Roche Ag Novel piperidine derivatives
CA2978066A1 (en) 2015-03-19 2016-09-22 E I Du Pont De Nemours And Company Fungicidal pyrazoles
BR112017028492B1 (pt) 2015-07-02 2023-12-26 Centrexion Therapeutics Corporation Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica
WO2018106959A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10391987B2 (en) * 2017-05-24 2019-08-27 Trw Automotives U.S. Llc Method for controlling a vehicle
TWI832917B (zh) 2018-11-06 2024-02-21 美商富曼西公司 經取代之甲苯基殺真菌劑
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
UY39189A (es) 2020-05-06 2021-12-31 Fmc Corp Fungicidas de tolilo sustituido y sus mezclas
CN114716389A (zh) * 2021-12-31 2022-07-08 北京岳达生物科技有限公司 一种3,5-二乙基异恶唑-4-羧酸的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6140266A (ja) 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピラゾ−ル誘導体
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5987135A (en) 1997-07-25 1999-11-16 Prc Inc. System and method for controlling and monitoring remote distributed processing system
WO2001040227A1 (fr) * 1999-12-03 2001-06-07 Ono Pharmaceutical Co., Ltd. Derives triazaspiro[5.5]undecane et medicaments contenant ces derives en tant que principe actif
DE60234453D1 (de) 2001-07-02 2009-12-31 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
DE10149370A1 (de) 2001-10-06 2003-04-10 Merck Patent Gmbh Pyrazolderivate
ATE455104T1 (de) 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
AU2003295041A1 (en) 2002-11-20 2004-06-18 L'oreal Composition for hair care or eyelashes containing a pyrazol-carboxamide, its use for stimulating hair and eyelash growth and/or for preventing loss thereof
WO2004076418A1 (en) * 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
DE10315572A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
UA82917C2 (en) * 2003-12-18 2008-05-26 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptor
CA2554671A1 (en) * 2004-02-10 2005-08-18 F.Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
DE102004014296A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
EP1762568A1 (en) 2004-07-01 2007-03-14 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
RU2007108296A (ru) * 2004-08-06 2008-09-20 Дайити Фармасьютикал Ко., Лтд. (JP) Производные пиразола
WO2006089076A2 (en) 2005-02-18 2006-08-24 Neurogen Corporation Thiazole amides, imidazole amides and related analogues
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
KR20080066938A (ko) * 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
CA2673359A1 (en) 2006-12-18 2008-06-26 7Tm Pharma A/S Cb1 receptor modulators

Also Published As

Publication number Publication date
CA2693187A1 (en) 2009-01-29
RU2010106397A (ru) 2011-09-10
EP2182953A2 (en) 2010-05-12
AR067674A1 (es) 2009-10-21
US20090029963A1 (en) 2009-01-29
PE20090893A1 (es) 2009-07-15
TW200911785A (en) 2009-03-16
US7977358B2 (en) 2011-07-12
AU2008280186A1 (en) 2009-01-29
SG175583A1 (en) 2011-11-28
JP2010534631A (ja) 2010-11-11
WO2009013211A3 (en) 2009-04-23
WO2009013211A2 (en) 2009-01-29
KR20100039416A (ko) 2010-04-15
CN101765430A (zh) 2010-06-30
BRPI0813836A2 (pt) 2015-01-06

Similar Documents

Publication Publication Date Title
CL2008002161A1 (es) Compuestos derivados de pirazol de fórmula (i); procedimiento de preparación; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad oclusiva de arterias, angina inestable, paro cardíaco, isquemia, cardiomiopatía, enfermedad de crohn, esclerosis múltiple, dolor neuropático.
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
CL2008000835A1 (es) Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
CL2008000127A1 (es) Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
CO6390101A2 (es) Compuestos purina
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
EA201391018A1 (ru) Препараты иммуносупрессантов
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
SV2004001756A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoraradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
PE20210928A1 (es) Mezclas pesticidas que comprenden indazoles
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
CL2007002637A1 (es) Compuestos derivados de acido 2-fenoxinicotinico; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de dislipidemias, arteriosclerosis e insuficiencia cardiaca.
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica